Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. NORDIC GROWTH MARKET
  5. Curasight A/S
  6. News
  7. Summary
    CURAS   DK0061295797

CURASIGHT A/S

(CURAS)
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Curasight A/S : warrant exercise registered at Erhvervsstyrelsen

10/13/2021 | 01:01am EST

On Thursday, 7 October 2021, the exercise period for Curasight A/S ("Curasight" or "the Company") warrants of series TO 1 ("TO 1") ended. The warrant exercise has now been registered at Erhvervsstyrelsen. The total number of registered shares now amounts to 19,893,891 shares and the share capital amounts to DKK 994,694.55. The conversion from interim shares to ordinary shares will be made on Friday, 15 October 2021, and new shares are expected to be in each of the shareholders' accounts around Monday, 18 October 2021.

For further information regarding the warrants of series TO 1, please contact:

Sedermera Fondkommission

+46 40 615 14 10

info@sedermera.se

www.sedermera.se

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

+45 22 83 01 60

uk@curasight.com

www.curasight.com

Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology provides improved diagnosis and risk stratification in multiple cancer types.  

https://news.cision.com/curasight/r/curasight-a-s-warrant-exercise-registered-at-erhvervsstyrelsen,c3431422

https://mb.cision.com/Main/19744/3431422/1480043.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about CURASIGHT A/S
11/25Interim report January - September 2021
AQ
11/25Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/23Curasight presents at HC Andersen Capital
AQ
10/15CURASIGHT A/S : presents at Økonomisk Ugebrev Life Science Investor Conference in Copenhag..
AQ
10/15CURASIGHT A/S : presents at BioStock Life Science Summit 20 October 2021
AQ
10/13CURASIGHT A/S : warrant exercise registered at Erhvervsstyrelsen
AQ
10/11CURASIGHT A/S : receives approximately DKK 47.6 million through exercise of warrants of se..
AQ
09/30CURASIGHT A/S : warrant TO 1 - last day of trading is Tuesday 5 October 2021
AQ
09/16CURASIGHT A/S : The exercise period for warrants of series TO 1 in Curasight A/S begins to..
AQ
09/01CURASIGHT A/S : strengthens its institutional investor base
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -5,55 M -0,84 M -0,84 M
Net cash 2020 36,3 M 5,52 M 5,52 M
P/E ratio 2020 -84,2x
Yield 2020 -
Capitalization 577 M 87,8 M 87,7 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 2
Free-Float 99,0%
Chart CURASIGHT A/S
Duration : Period :
Curasight A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Ulrich A. Krasilnikoff Chief Executive & Financial Officer, Director
Per Falholt Chairman
Andreas Kjaer Chief Scientific Officer & Director
Carsten Haagen Nielsen Pre-Clinical Director
Lars Trolle Deputy Chairman
Sector and Competitors
1st jan.Capi. (M$)
CURASIGHT A/S7.61%88
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431